Individualizing Hormone Therapy to Minimize Risk

Accurate Assessment of Risks and Benefits

Donna Shoupe


Women's Health. 2011;7(4):475-485. 

In This Article

Future Perspective

Within the next 5 years, the results of both the Early Versus Late Intervention Trial With Estradiol (ELITE) and Kronos Early Estrogen Prevention Study (KEEPS) trial will be available.[1,101] These trials are designed to further clarify the cardiovascular protective effects of estrogen replacement when given to women in their early menopause years compared with those that have 10 years or more of menopause. If these trials demonstrate a protective effect of estrogen against atherosclerotic plaque formation, a very compelling argument for initiating estrogen therapy in the early menopause will be difficult to counter. Estrogen is already an established medication for preventing bone loss and treating menopausal symptoms in the early menopause. It is also expected that new low-dose estrogen only and combination products with new progestins will be introduced that will increase the choices for the large numbers of women entering the menopause. It is anticipated that within the next decade, healthcare providers and the general public will have a better and a more accurate understanding of the low risks associated with hormone therapy and that the accepted benefits associated with the initiation of hormone therapy for postmenopausal women within 10 years of their menopause will include protection from cardiovascular disease, prevention of bone loss, and effective treatment of menopausal symptoms.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.